about
Acetyl-L-carnitine for patients with hepatic encephalopathyNutrition therapy: Integral part of liver transplant careInflammation: A novel target of current therapies for hepatic encephalopathy in liver cirrhosisGut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemiaManagement of overt hepatic encephalopathyIntestinal microbiota in health and disease: role of bifidobacteria in gut homeostasisThe conservative and interventional treatment of the complications of liver cirrhosis: Part 2 of a series on liver cirrhosisGut microbiota and liver diseasesIntestinal permeability in a patient with liver cirrhosisMicrobiota and neurologic diseases: potential effects of probioticsPsychobiotics and the gut-brain axis: in the pursuit of happinessEngineering the gut microbiota to treat hyperammonemia.Systematic review and meta-analysis of randomized trials on probiotics for hepatic encephalopathy.Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis.Covert and Overt Hepatic Encephalopathy: Diagnosis and ManagementProbiotics, prebiotics, and synbiotics: gut and beyondComparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessmentProbiotics and liver diseaseA current review of the diagnostic and treatment strategies of hepatic encephalopathy.Clinical science workshop: targeting the gut-liver-brain axis.Hepatic encephalopathy: a critical current review.Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.Probiotics for people with hepatic encephalopathy.Using probiotics in clinical practice: Where are we now? A review of existing meta-analyses.Serum level of taurine would be associated with the amelioration of minimal hepatic encephalopathy in cirrhotic patients.Gut Microbiome-based Therapeutics in Liver Cirrhosis: Basic Consideration for the Next Step.Prevention and treatment of hepatic encephalopathy: focusing on gut microbiota.Multistrain probiotic and lactulose in the treatment of minimal hepatic encephalopathy.Oral l-ornithine-l-aspartate in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled trial.Fecal microbiota transplantation prevents hepatic encephalopathy in rats with carbon tetrachloride-induced acute hepatic dysfunction.The Pharmabiotic Approach to Treat Hyperammonemia.Role of gut microbiota and oxidative stress in the progression of non-alcoholic fatty liver disease to hepatocarcinoma: Current and innovative therapeutic approaches.Probiotics and gastrointestinal conditions: An overview of evidence from the Cochrane Collaboration.l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.Update on the Therapeutic Management of Hepatic Encephalopathy.Elucidation of the anti-hyperammonemic mechanism of Lactobacillus amylovorus JBD401 by comparative genomic analysis.Is there a role for probiotics in liver disease?
P2860
Q24187553-5F2177F3-5094-4172-A4A3-C1D521BD4974Q26773248-FE871021-FEA0-47D2-9C9E-93CAB193112FQ26778000-61383528-61F5-4DCC-9D4F-CE747DBBAA02Q26826919-C34C37C8-7FFB-47FE-91A4-FEF964C68B31Q26830789-781E4BB7-61DF-48A4-9830-EEA66B5B24A2Q27001712-F8033826-1AAC-46D9-B907-6414352E6977Q27009164-FC59316B-A983-48D9-8308-26A325076848Q27015127-B083C3A9-DEBC-4D47-B544-59E001E7DEBAQ28067113-1F1123DF-6EB1-4D73-B3C3-433DDFD44B46Q28076752-AB3794B7-A1A8-4D72-94D0-5E9457B3A037Q28088318-CAA167C2-A4BA-4EA1-8E03-2F60F451DD4AQ30664039-1E16FD7A-3301-41FD-84C8-E255646404F6Q34252801-9A5FD815-EF84-4EDC-92C2-E1DA7289FB64Q35120488-86BD6E67-828A-4E6F-BE6B-7B54866F8669Q36199772-07CC293E-D0D5-4B9A-9DA1-CFEEBC4F2A33Q36282616-CA55D18A-A9C8-4C4A-82A0-F40474FC5EA1Q36603392-6BCA59E9-D4D6-46E5-A336-6D934D3CB1BEQ37372411-0A845BEA-2DE7-4860-BD65-166E3FA7B79DQ38058329-9AA33502-680B-446E-B290-CFDC60788448Q38601692-96A67283-ABAE-4C80-9699-D60C291F35FFQ38645107-43D6BB8B-5981-4712-818C-95E0B96D93FBQ38835093-2DAE9C2D-485C-4998-A073-E3C5884594AAQ38946102-CC38266C-4FFA-416F-BF53-9E8FE31644FFQ39391152-45DE5CF5-8926-48D4-A76E-5EE8557C1F92Q41082489-655F0383-A4AB-440E-A395-679F64635E17Q41706834-509C490A-B1D6-42F4-99A8-D48EE46BC7C0Q42407730-3DBE50BA-5BC6-4893-B9CE-055444B008FBQ43010311-967805D1-81D5-4447-9AC1-2FE357A5A6F6Q45310576-A0798606-FFF9-47E1-A3E0-F9AC09F40A7EQ47162191-A5A9023E-BD52-4DDB-A429-29518D6E13D2Q47831420-4A1B1172-2CDA-4DA1-B431-052DB529FEB6Q50136712-48270F0E-A434-466F-B167-604BB2697B16Q50224112-5DA640DB-9CEB-45C1-ADCE-D28D57476D48Q51344453-5C914CB2-989A-45D8-BD2E-3518693CABD0Q55312369-0771C4F2-2446-40B2-A414-FEEDF1752DB2Q55359089-72A4DA71-2EDE-4315-A4FA-5B61DD10D248Q59101131-271191D1-414C-4970-BB6E-0A624F48CF85
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Probiotics for patients with hepatic encephalopathy
@ast
Probiotics for patients with hepatic encephalopathy
@en
Probiotics for patients with hepatic encephalopathy
@en-gb
Probiotics for patients with hepatic encephalopathy
@nl
type
label
Probiotics for patients with hepatic encephalopathy
@ast
Probiotics for patients with hepatic encephalopathy
@en
Probiotics for patients with hepatic encephalopathy
@en-gb
Probiotics for patients with hepatic encephalopathy
@nl
prefLabel
Probiotics for patients with hepatic encephalopathy
@ast
Probiotics for patients with hepatic encephalopathy
@en
Probiotics for patients with hepatic encephalopathy
@en-gb
Probiotics for patients with hepatic encephalopathy
@nl
P2093
P2860
P3181
P1476
Probiotics for patients with hepatic encephalopathy
@en
P2093
Angela C Webster
Anouk Bakens
Kerrie Wiley
Richard G McGee
Stephen M Riordan
P2860
P3181
P356
10.1002/14651858.CD008716.PUB2
P577
2011-11-09T00:00:00Z